SRR13311164
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYC_TARGETS_V2+0.560
- MYC_TARGETS_V1+0.460
- TGF_BETA_SIGNALING+0.380
- OXIDATIVE_PHOSPHORYLATION+0.340
- UNFOLDED_PROTEIN_RESPONSE+0.340
- PROTEIN_SECRETION+0.320
- MTORC1_SIGNALING+0.300
- P53_PATHWAY+0.290
- WNT_BETA_CATENIN_SIGNALING+0.290
- DNA_REPAIR+0.270
Top 10 suppressed
- ALLOGRAFT_REJECTION-0.370
- PANCREAS_BETA_CELLS-0.370
- HEDGEHOG_SIGNALING-0.350
- INTERFERON_GAMMA_RESPONSE-0.300
- INTERFERON_ALPHA_RESPONSE-0.240
- INFLAMMATORY_RESPONSE-0.230
- KRAS_SIGNALING_DN-0.210
- SPERMATOGENESIS-0.200
- COMPLEMENT-0.170
- KRAS_SIGNALING_UP-0.170
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR23303753 | — | — | 0.839 |
| 2 | R205 | — | — | 0.809 |
| 3 | MDT-AP-3295 | Med | Medulloblastoma | 0.808 |
| 4 | DRR168575 | — | — | 0.807 |
| 5 | A6FB1BEE-0D36-480C-8619-1FA82583FCD1 | — | — | 0.804 |
| 6 | SRR650156 | — | — | 0.800 |
| 7 | 9B1A0E7C-F8DB-4FA0-9259-42A988D4E040 | — | — | 0.798 |
| 8 | MNG449 | — | — | 0.796 |
| 9 | MNG666 | — | — | 0.792 |
| 10 | R122 | — | — | 0.792 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 26 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYC_TARGETS_V2 | 0.560 | Idelalisib | — uncovered |
| MYC_TARGETS_V1 | 0.460 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.380 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.340 | Remibrutinib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.340 | Idelalisib | — uncovered |
| PROTEIN_SECRETION | 0.320 | Remibrutinib | — uncovered |
| MTORC1_SIGNALING | 0.300 | Inavolisib | — uncovered |
| P53_PATHWAY | 0.290 | Idelalisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.290 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.270 | Idelalisib | — uncovered |
| ADIPOGENESIS | 0.260 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.260 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.220 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.220 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.180 | Inavolisib | — uncovered |
| HYPOXIA | 0.170 | Idelalisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.160 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.160 | Inavolisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.130 | Inavolisib | — uncovered |
| APOPTOSIS | 0.120 | Idelalisib | — uncovered |